Cardiff Oncology, Inc. ( (CRDF) ) has released its Q3 earnings. Here is a breakdown of the information Cardiff Oncology, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cardiff Oncology, Inc. is a clinical-stage biotechnology company based in San Diego, California, focusing on developing novel cancer therapies through Polo-like Kinase 1 inhibition. The latest earnings report for the quarter ending September 30, 2025, highlights a decrease in revenues and an increase in net losses compared to the previous year. Key financial metrics include a net loss of $11.3 million for the quarter and $38.7 million for the nine months, with research and development expenses rising due to ongoing clinical trials. The company continues to focus on its lead drug candidate, onvansertib, which is being tested in various cancer indications. Despite the financial challenges, Cardiff Oncology remains committed to advancing its clinical programs and exploring strategic opportunities to enhance its pipeline.